Literature DB >> 26492180

Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.

Martin Köbel1, Bo Meng2, Lien N Hoang3, Noorah Almadani3, Xiaodong Li2, Robert A Soslow4, C Blake Gilks3, Cheng-Han Lee2.   

Abstract

Mixed endometrial carcinoma refers to a tumor that comprises 2 or more distinct histotypes. We studied 18 mixed-type endometrial carcinomas-11 mixed serous and low-grade endometrioid carcinomas (SC/EC), 5 mixed clear cell and low-grade ECs (CCC/EC), and 2 mixed CCC and SCs (CCC/SC), using targeted next-generation sequencing and immunohistochemistry to compare the molecular profiles of the different histotypes present in each case. In 16 of 18 cases there was molecular evidence that both components shared a clonal origin. Eight cases (6 EC/SC, 1 EC/CCC, and 1 SC/CCC) showed an SC molecular profile that was the same in both components. Five cases (3 CCC/EC and 2 SC/EC) showed a shared endometrioid molecular profile and identical mismatch-repair protein deficiency in both components. A single SC/EC case harbored the same POLE exonuclease domain mutation in both components. One SC/CCC and 1 EC/CCC case showed both shared and unique molecular features in the 2 histotype components, suggesting early molecular divergence from a common clonal origin. In 2 cases, there were no shared molecular features, and these appear to be biologically unrelated synchronous tumors. Overall, these results show that the different histologic components in mixed endometrial carcinomas typically share the same molecular aberrations. Mixed endometrial carcinomas most commonly occur through morphologic mimicry, whereby tumors with serous-type molecular profile show morphologic features of EC or CCC, or through underlying deficiency in DNA nucleotide repair, with resulting rapid accrual of mutations and intratumoral phenotypic heterogeneity. Less commonly, mixed endometrial carcinomas are the result of early molecular divergence from a common progenitor clone or are synchronous biologically unrelated tumors (collision tumors).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26492180      PMCID: PMC5029122          DOI: 10.1097/PAS.0000000000000536

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  39 in total

1.  Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.

Authors:  M K McConechy; A Talhouk; H H Li-Chang; S Leung; D G Huntsman; C B Gilks; J N McAlpine
Journal:  Gynecol Oncol       Date:  2015-01-28       Impact factor: 5.482

2.  Pure compared with mixed serous endometrial carcinoma: two different entities?

Authors:  Thijs Roelofsen; Maaike A P C van Ham; Johanna M Wiersma van Tilburg; Saskia F Zomer; Mijke Bol; Leon F A G Massuger; Johan Bulten
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

3.  Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

Authors:  Lien N Hoang; Melissa K McConechy; Martin Köbel; Guangming Han; Marjan Rouzbahman; Ben Davidson; Julie Irving; Rola H Ali; Sam Leung; Jessica N McAlpine; Esther Oliva; Marisa R Nucci; Robert A Soslow; David G Huntsman; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

4.  Mixed serous-endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinoma.

Authors:  K.E. Williams; E.D. Waters; R.P. Woolas; I.G. Hammond; A.J. McCartney
Journal:  Int J Gynecol Cancer       Date:  1994-01       Impact factor: 3.437

5.  Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.

Authors:  Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Janine Senz; Christine Chow; Alireza Heravi-Moussavi; Gregg B Morin; Anne-Marie Mes-Masson; Mark S Carey; Jessica N McAlpine; Janice S Kwon; Leah M Prentice; Niki Boyd; Sohrab P Shah; C Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-03-07       Impact factor: 7.996

6.  Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.

Authors:  Anna Yemelyanova; Hongxiu Ji; Ie-Ming Shih; Tian-Li Wang; Lee-Shu-Fune Wu; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2009-10       Impact factor: 6.394

7.  Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Authors:  Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

8.  Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.

Authors:  R I Demopoulos; A F Mesia; K Mittal; E Vamvakas
Journal:  Int J Gynecol Pathol       Date:  1999-07       Impact factor: 2.762

9.  Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Shinsuke Aida; Hideyuki Shimazaki; Seiichi Tamai; Osamu Matsubara
Journal:  Hum Pathol       Date:  2007-04-18       Impact factor: 3.466

10.  Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).

Authors:  John E Burke; Olga Perisic; Glenn R Masson; Oscar Vadas; Roger L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

View more
  12 in total

Review 1.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

Review 2.  Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.

Authors:  Stephanie R Barbari; Polina V Shcherbakova
Journal:  DNA Repair (Amst)       Date:  2017-06-09

3.  Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.

Authors:  Mackenzie Coatham; Xiaodong Li; Anthony N Karnezis; Lien N Hoang; Basile Tessier-Cloutier; Bo Meng; Robert A Soslow; C Blake Gilks; David G Huntsman; Colin J R Stewart; Lynne M Postovit; Martin Köbel; Cheng-Han Lee
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

4.  Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.

Authors:  Aline Talhouk; Lien N Hoang; Melissa K McConechy; Quentin Nakonechny; Joyce Leo; Angela Cheng; Samuel Leung; Winnie Yang; Amy Lum; Martin Köbel; Cheng-Han Lee; Robert A Soslow; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Gynecol Oncol       Date:  2016-07-14       Impact factor: 5.482

Review 5.  New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.

Authors:  A Talhouk; J N McAlpine
Journal:  Gynecol Oncol Res Pract       Date:  2016-12-13

6.  Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.

Authors:  Manouk van Esterik; Inge C Van Gool; Cor D de Kroon; Remi A Nout; Carien L Creutzberg; Vincent T H B M Smit; Tjalling Bosse; Ellen Stelloo
Journal:  Oncotarget       Date:  2017-04-11

7.  Functional Analysis of Cancer-Associated DNA Polymerase ε Variants in Saccharomyces cerevisiae.

Authors:  Stephanie R Barbari; Daniel P Kane; Elizabeth A Moore; Polina V Shcherbakova
Journal:  G3 (Bethesda)       Date:  2018-03-02       Impact factor: 3.154

Review 8.  Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.

Authors:  Martin Köbel; Brigitte M Ronnett; Naveena Singh; Robert A Soslow; C Blake Gilks; W Glenn McCluggage
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

9.  Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.

Authors:  Eun Young Kang; Nicholas Jp Wiebe; Christa Aubrey; Cheng-Han Lee; Michael S Anglesio; Derek Tilley; Prafull Ghatage; Gregg S Nelson; Sandra Lee; Martin Köbel
Journal:  J Pathol Clin Res       Date:  2021-10-01

Review 10.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.